Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

MLA

Phillips, Kelly-Anne, et al. “Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 31, no. 25, Sept. 2013, pp. 3091–99. EBSCOhost, https://doi.org/10.1200/JCO.2012.47.8313.

APA

Phillips, K.-A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., Buys, S. S., Andrieu, N., Noguès, C., Stoppa-Lyonnet, D., Bonadona, V., Pujol, P., McLachlan, S. A., John, E. M., Hooning, M. J., … Hopper, J. L. (2013). Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31(25), 3091–3099. https://doi.org/10.1200/JCO.2012.47.8313

Chicago

Phillips, Kelly-Anne, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, et al. 2013. “Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31 (25): 3091–99. doi:10.1200/JCO.2012.47.8313.